GLP-1 medicines while breastfeeding: milk transfer and what is still unknown
Milk studies for injected semaglutide, oral semaglutide and tirzepatide answer different questions. Results below a test’s detection limit do not establish long-term infant outcomes.
GLP-1 lactation evidence depends on the drug and formulation. A small study did not detect injected semaglutide in sampled human milk. Wegovy tablets have a separate label concern about an absorption enhancer, SNAC. The Zepbound label describes low or undetectable milk levels in a single-dose tirzepatide study. These findings do not establish long-term infant effects or effects on milk production.123
Start with the name and route
“Semaglutide” identifies a drug, but a tablet and an injection can present different exposures. The Wegovy oral label describes semaglutide levels below the limit of quantification in milk in a lactation study. It also reports the presence of SNAC and/or its metabolites and identifies possible infant accumulation as the reason for a separate concern. The injection section addresses a formulation without the tablet enhancer and states evidence gaps for milk, infants and milk production.1
The separate published injected-semaglutide study sampled milk from eight people and did not detect semaglutide in those samples. That observation describes the assay, the times sampled and the people in the study. It does not prove zero transfer under all circumstances. Nor does it resolve outcomes in newborns or establish how a longer exposure could affect infant development or milk supply.2
Read the tirzepatide study as a separate exposure
The Zepbound prescribing information describes milk sampling after a single exposure in 11 healthy lactating adults. Most samples had no detectable tirzepatide, and the detected amount in the remaining samples was low relative to the maternal dose. The label reports no available data on effects in breastfed infants or on milk production. A study based on one exposure and measured concentrations cannot answer the same question as follow-up of infants during ongoing use.3
| Evidence term | What it lets you conclude |
|---|---|
| Not detected | The assay did not find the drug in the samples tested at its detection limit. |
| Not quantified | A concentration could not be reliably measured by the assay. |
| Low transfer | A study measured a small amount under its particular conditions. |
| Infant outcomes | A separate question requiring appropriate infant follow-up. |
Three different unknowns can survive one milk test
A milk concentration result addresses transfer in the samples tested. A separate question is whether an infant absorbs an ingredient, which can depend on the ingredient and the infant’s circumstances. A third question is whether milk production or feeding outcomes change over time. The Wegovy and Zepbound labels make these evidence categories visible. A result with a low or unmeasurable concentration does not provide follow-up on all of them. If a clinician is explaining why two products have different lactation language, ask which of these questions the cited study answered.123
Give both clinicians the same product record
A postpartum care clinician and the person prescribing a GLP-1 medicine need the exact product name, route, reason for treatment and relevant infant and feeding history. If the name is unclear, the pharmacy can identify the dispensed product. Ask how the clinicians will coordinate their assessment and who will answer questions if the product or feeding circumstances change.123
When reviewing medical weight management services, ask what support the practice provides for coordinating with postpartum or pediatric care. The pregnancy and contraception guide covers a different set of label questions. Milk transfer and infant outcomes require their own evidence.
Sources
- National Library of Medicine DailyMed. WEGOVY semaglutide injection and tablets prescribing information. Section 8.2 gives distinct lactation information for the two routes and describes the oral formulation’s SNAC concern. Accessed .
- PubMed / original research. Subcutaneous Semaglutide during Breastfeeding: Infant Safety Regarding Drug Transfer into Human Milk. Original eight-person milk sampling study. The sample and measurement method do not establish long-term infant outcomes. Accessed .
- U.S. Food and Drug Administration. ZEPBOUND tirzepatide prescribing information. Section 8.2 summarizes single-dose milk testing in 11 adults and evidence gaps for infants and milk production. Accessed .